BACKGROUND: Acute kidney injury (AKI) occurs in 26% of trauma patients and is associated with increased mortality and risk for nosocomial infections (NCIs). We compared serial plasma cytokine levels in patients with posttraumatic AKI to determine whether the early cytokine changes are associated with the occurrence of AKI and NCI. METHODS: We performed a secondary analysis of the Inflammation and the Host Response to Injury database to include adult blunt trauma patients who had available plasma proteomic analyses. AKI was defined by the RIFLE (Risk, Injury, Failure, Loss, and End-stage Kidney) classification, which requires a 50% increase in serum creatinine. The association among AKI, NCI, and plasma cytokines was analyzed using a mixed model analyses and logistic regression. RESULTS: Among 147 patients in the cohort, prevalence of NCI was 73% and 52% for patients with and without AKI, respectively. In mixed model analyses adjusted for clinical factors, AKI patients developed significant early increase in IL-1ra, IL-8, MCP1, and IL-6; early decrease in sTNFR2; and late decrease in IL-1ra, IL-4, and IL-6 concentrations, compared with patients without AKI and regardless of NCI. The change in cytokine pattern differed for sIL1R2, CXCL1, and MIP1β, depending on the occurrence of NCI. Patients with AKI and NCI had lower early and late sIL1R2 and higher early and late CXCL1 and MIP1β levels. Within the first 24 hours of injury, adding plasma levels of IL-1ra, IL-8, MCP1, IL-6, and sTNFR2 to clinical parameters of injury severity provided a predictive model for AKI superior to clinical model only (p < 0.001). CONCLUSION: AKI trauma patients exhibit simultaneous changes in proinflammatory and anti-inflammatory serial plasma cytokine levels. The predictive model for AKI that combines plasma cytokine levels with clinical data within 24 hours of injury requires further prospective validation in larger studies. LEVEL OF EVIDENCE: Prognostic study, level III.
BACKGROUND:Acute kidney injury (AKI) occurs in 26% of traumapatients and is associated with increased mortality and risk for nosocomial infections (NCIs). We compared serial plasma cytokine levels in patients with posttraumatic AKI to determine whether the early cytokine changes are associated with the occurrence of AKI and NCI. METHODS: We performed a secondary analysis of the Inflammation and the Host Response to Injury database to include adult blunt traumapatients who had available plasma proteomic analyses. AKI was defined by the RIFLE (Risk, Injury, Failure, Loss, and End-stage Kidney) classification, which requires a 50% increase in serum creatinine. The association among AKI, NCI, and plasma cytokines was analyzed using a mixed model analyses and logistic regression. RESULTS: Among 147 patients in the cohort, prevalence of NCI was 73% and 52% for patients with and without AKI, respectively. In mixed model analyses adjusted for clinical factors, AKI patients developed significant early increase in IL-1ra, IL-8, MCP1, and IL-6; early decrease in sTNFR2; and late decrease in IL-1ra, IL-4, and IL-6 concentrations, compared with patients without AKI and regardless of NCI. The change in cytokine pattern differed for sIL1R2, CXCL1, and MIP1β, depending on the occurrence of NCI. Patients with AKI and NCI had lower early and late sIL1R2 and higher early and late CXCL1 and MIP1β levels. Within the first 24 hours of injury, adding plasma levels of IL-1ra, IL-8, MCP1, IL-6, and sTNFR2 to clinical parameters of injury severity provided a predictive model for AKI superior to clinical model only (p < 0.001). CONCLUSION:AKI traumapatients exhibit simultaneous changes in proinflammatory and anti-inflammatory serial plasma cytokine levels. The predictive model for AKI that combines plasma cytokine levels with clinical data within 24 hours of injury requires further prospective validation in larger studies. LEVEL OF EVIDENCE: Prognostic study, level III.
Authors: Thomas S Hoke; Ivor S Douglas; Christina L Klein; Zhibin He; Wenfeng Fang; Joshua M Thurman; Yunxia Tao; Belda Dursun; Norbert F Voelkel; Charles L Edelstein; Sarah Faubel Journal: J Am Soc Nephrol Date: 2006-12-13 Impact factor: 10.121
Authors: Patricia A Manderscheid; Ryan P Bodkin; Bruce A Davidson; Erik Jensen; Thomas A Russo; Paul R Knight Journal: Clin Diagn Lab Immunol Date: 2004-07
Authors: Wenzhong Xiao; Michael N Mindrinos; Junhee Seok; Joseph Cuschieri; Alex G Cuenca; Hong Gao; Douglas L Hayden; Laura Hennessy; Ernest E Moore; Joseph P Minei; Paul E Bankey; Jeffrey L Johnson; Jason Sperry; Avery B Nathens; Timothy R Billiar; Michael A West; Bernard H Brownstein; Philip H Mason; Henry V Baker; Celeste C Finnerty; Marc G Jeschke; M Cecilia López; Matthew B Klein; Richard L Gamelli; Nicole S Gibran; Brett Arnoldo; Weihong Xu; Yuping Zhang; Steven E Calvano; Grace P McDonald-Smith; David A Schoenfeld; John D Storey; J Perren Cobb; H Shaw Warren; Lyle L Moldawer; David N Herndon; Stephen F Lowry; Ronald V Maier; Ronald W Davis; Ronald G Tompkins Journal: J Exp Med Date: 2011-11-21 Impact factor: 14.307
Authors: Min Xu; Xuanchuan Wang; Babak Banan; Danielle L Chirumbole; Sandra Garcia-Aroz; Aparna Balakrishnan; Deepak K Nayak; Zhengyan Zhang; Jianluo Jia; Gundumi A Upadhya; Joseph P Gaut; Ronald Hiebsch; Pamela T Manning; Ningying Wu; Yiing Lin; William C Chapman Journal: Am J Transplant Date: 2017-12-02 Impact factor: 8.086
Authors: Dmytro Korenkevych; Tezcan Ozrazgat-Baslanti; Paul Thottakkara; Petar Momcilovic; Azra Bihorac; Charles E Hobson; Panos Pardalos Journal: Ann Surg Date: 2016-06 Impact factor: 12.969
Authors: Ahmed Farhat; Areg Grigorian; Ninh T Nguyen; Brian Smith; Barbara J Williams; Sebastian D Schubl; Victor Joe; Dawn Elfenbein; Jeffry Nahmias Journal: Eur J Trauma Emerg Surg Date: 2019-05-20 Impact factor: 3.693
Authors: Dennis G Moledina; Selin Isguven; Eric McArthur; Heather Thiessen-Philbrook; Amit X Garg; Michael Shlipak; Richard Whitlock; Peter A Kavsak; Steven G Coca; Chirag R Parikh Journal: Ann Thorac Surg Date: 2017-02-21 Impact factor: 4.330
Authors: David A C Messerer; Rebecca Halbgebauer; Bo Nilsson; Hermann Pavenstädt; Peter Radermacher; Markus Huber-Lang Journal: Nat Rev Nephrol Date: 2020-09-21 Impact factor: 28.314